Rapid decline in HCV incidence among people who inject drugs associated with national scale-up in coverage of a combination of harm reduction interventions.
about
Ethical considerations of e-cigarette use for tobacco harm reductionThe hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for preventionPublic health and international drug policy.Monitoring quality and coverage of harm reduction services for people who use drugs: a consensus study.Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland.Discrepancies in prevalence trends for HIV, hepatitis B virus, and hepatitis C virus in Haiphong, Vietnam from 2007 to 2012.The successful implementation of Scotland's Hepatitis C Action Plan: what can other European stakeholders learn from the experience? A Scottish voluntary sector perspectiveDisinfection of syringes contaminated with hepatitis C virus by rinsing with household products.Risk behaviour determinants among people who inject drugs in Stockholm, Sweden over a 10-year period, from 2002 to 2012.Scaling up HCV prevention and treatment interventions in rural USA - model projections for tackling an increasing epidemic.Mobilising a global response to hepatitis: Lessons learned from the HIV movement.Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005-2014: The HITS-p study.Prevention knowledge, risk behaviours and seroprevalence among nonurban injectors of southwest ConnecticutNeedle syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis.Prevalence of hepatitis C and pre-testing awareness of hepatitis C status in 1500 consecutive PWID participants at the Stockholm needle exchange program.Strategies for the treatment of Hepatitis C in an era of interferon-free therapies: what public health outcomes do we value most?Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs.Incidence and Risk Factors for Hepatitis C Virus Infection among Illicit Drug Users in Italy.Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe".Importance and Contribution of Community, Social, and Healthcare Risk Factors for Hepatitis C Infection in Pakistan.HIV and Viral Hepatitis Among Imprisoned Key Populations.Strategies for the elimination of hepatitis C virus infection as a public health threat in the United StatesImpact of current and scaled-up levels of hepatitis C prevention and treatment interventions for people who inject drugs in three UK settings-what is required to achieve the WHO's HCV elimination targets?
P2860
Q26749334-BC2E0F6A-4D1D-4648-A083-781D90DF5FAAQ26801456-94880021-226A-48FC-9C34-962220DA7DB5Q30377895-5CB85FE3-3AC5-4892-ABF1-F38873032FE7Q33592665-0AAF2159-2F87-41AC-A421-22F9B5C63255Q33769960-47E3FB36-6927-431B-BCAE-EC4198426AB4Q33853905-8F7FF897-A78E-4379-9DCA-D871232FD890Q34261054-A29C753C-EB6D-4CCF-AB99-F09511251650Q35628270-CD12650F-6AA0-4DD3-9FEB-79E9330EE081Q38372109-5A989946-1C99-48B9-A974-0A6583B2C7E2Q38666907-16FD3273-892D-4F51-A911-E3BCF877FDA9Q38810895-A86BAD0A-17FE-4667-A914-8DEDEF88032DQ38931620-26CB75B8-CC02-4D7C-AE74-83774ED90F39Q39855070-DECD2D6A-BDE6-4EBA-92E5-3300EE7D4E60Q40048259-35BFEF67-FBCC-4D56-A318-468BCEA8301AQ40176014-00B4BECB-D639-4790-864A-38DE29CC88E5Q41672541-F2567FF9-3ECE-4CE0-81B3-0C0BA4871ABFQ42720607-BC9F2984-2C71-4867-ABA4-3B75ABB8A181Q45323809-03D1E0B7-C0C8-4C2E-B45C-7CB287D9A51FQ46084794-E5F0F438-CF97-4761-ADD1-4D7FC279A1A1Q47579352-5F5B6EC0-91D7-4B1B-A18C-E54375893F40Q53403318-7065524A-2E8A-4B91-841B-93E58B406338Q57193075-0BC3B65D-DEE0-4FED-88BD-7A89F79E5876Q57700826-C4395F5B-F2F0-482A-9F45-80B0E8470F56
P2860
Rapid decline in HCV incidence among people who inject drugs associated with national scale-up in coverage of a combination of harm reduction interventions.
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Rapid decline in HCV incidence ...... harm reduction interventions.
@ast
Rapid decline in HCV incidence ...... harm reduction interventions.
@en
Rapid decline in HCV incidence ...... harm reduction interventions.
@nl
type
label
Rapid decline in HCV incidence ...... harm reduction interventions.
@ast
Rapid decline in HCV incidence ...... harm reduction interventions.
@en
Rapid decline in HCV incidence ...... harm reduction interventions.
@nl
prefLabel
Rapid decline in HCV incidence ...... harm reduction interventions.
@ast
Rapid decline in HCV incidence ...... harm reduction interventions.
@en
Rapid decline in HCV incidence ...... harm reduction interventions.
@nl
P2093
P2860
P1433
P1476
Rapid decline in HCV incidence ...... harm reduction interventions.
@en
P2093
Avril Taylor
Celia Aitken
David J Goldberg
Georgina McAllister
Rory Gunson
Samantha J Shepherd
Sharon J Hutchinson
P2860
P304
P356
10.1371/JOURNAL.PONE.0104515
P407
P577
2014-08-11T00:00:00Z